Literature DB >> 16641275

Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo.

Feng-Qi An1, Hope Merlene Folarin, Nicole Compitello, Justin Roth, Stanton L Gerson, Keith R McCrae, Farnaz D Fakhari, Dirk P Dittmer, Rolf Renne.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease. Most KS tumor cells are latently infected with KSHV and are of endothelial origin. While PEL-derived cell lines maintain KSHV indefinitely, all KS tumor-derived cells to date have lost viral genomes upon ex vivo cultivation. To study KSHV latency and tumorigenesis in endothelial cells, we generated telomerase-immortalized human umbilical vein endothelial (TIVE) cells. TIVE cells express all KSHV latent genes 48 h postinfection, and productive lytic replication could be induced by RTA/Orf50. Similar to prior models, infected cultures gradually lost viral episomes. However, we also obtained, for the first time, two endothelial cell lines in which KSHV episomes were maintained indefinitely in the absence of selection. Long-term KSHV maintenance correlated with loss of reactivation in response to RTA/Orf50 and complete oncogenic transformation. Long-term-infected TIVE cells (LTC) grew in soft agar and proliferated under reduced-serum conditions. LTC, but not parental TIVE cells, formed tumors in nude mice. These tumors expressed high levels of the latency-associated nuclear antigen (LANA) and expressed lymphatic endothelial specific antigens as found in KS (LYVE-1). Furthermore, host genes, like those encoding interleukin 6, vascular endothelial growth factor, and basic fibroblast growth factor, known to be highly expressed in KS lesions were also induced in LTC-derived tumors. KSHV-infected LTCs represent the first xenograft model for KS and should be of use to study KS pathogenesis and for the validation of anti-KS drug candidates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641275      PMCID: PMC1472065          DOI: 10.1128/JVI.80.10.4833-4846.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells.

Authors:  Xuezhong Cai; Shihua Lu; Zhihong Zhang; Carlos M Gonzalez; Blossom Damania; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-30       Impact factor: 11.205

2.  Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus.

Authors:  Mark A Samols; Jianhong Hu; Rebecca L Skalsky; Rolf Renne
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  KSHV and Kaposi's sarcoma: the end of the beginning?

Authors:  D Ganem
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

4.  Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells.

Authors:  R Renne; D Blackbourn; D Whitby; J Levy; D Ganem
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).

Authors:  R Sarid; O Flore; R A Bohenzky; Y Chang; P S Moore
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Characterization of in vitro culture of HIV-negative Kaposi's sarcoma-derived cells. In vitro responses to alfa interferon.

Authors:  C Lebbé; P de Crémoux; G Millot; M P Podgorniak; O Verola; R Berger; P Morel; F Calvo
Journal:  Arch Dermatol Res       Date:  1997-06       Impact factor: 3.017

8.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.

Authors:  C Bais; B Santomasso; O Coso; L Arvanitakis; E G Raaka; J S Gutkind; A S Asch; E Cesarman; M C Gershengorn; E A Mesri; M C Gerhengorn
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

9.  Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA.

Authors:  Andrew Godfrey; John Anderson; Antigoni Papanastasiou; Yasu Takeuchi; Chris Boshoff
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

10.  KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway.

Authors:  S J Gao; C Boshoff; S Jayachandra; R A Weiss; Y Chang; P S Moore
Journal:  Oncogene       Date:  1997-10-16       Impact factor: 9.867

View more
  85 in total

1.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen and angiogenin interact with common host proteins, including annexin A2, which is essential for survival of latently infected cells.

Authors:  Nitika Paudel; Sathish Sadagopan; Sandhya Balasubramanian; Bala Chandran
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

2.  Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV.

Authors:  Tiffany Jones; Fengchun Ye; Roble Bedolla; Yufei Huang; Jia Meng; Liwu Qian; Hongyi Pan; Fuchun Zhou; Rosalie Moody; Brent Wagner; Mazen Arar; Shou-Jiang Gao
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

Review 3.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

4.  Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155.

Authors:  Rebecca L Skalsky; Mark A Samols; Karlie B Plaisance; Isaac W Boss; Alberto Riva; M Cecilia Lopez; Henry V Baker; Rolf Renne
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

5.  Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  Debasmita Roy; Dirk P Dittmer
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

Review 6.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

7.  Papillomavirus E2 protein is regulated by specific fibroblast growth factor receptors.

Authors:  Marsha DeSmet; Sriramana Kanginakudru; Leny Jose; Fang Xie; Timra Gilson; Elliot J Androphy
Journal:  Virology       Date:  2018-06-06       Impact factor: 3.616

8.  Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes.

Authors:  Vivek Vikram Singh; Nagaraj Kerur; Virginie Bottero; Sujoy Dutta; Sayan Chakraborty; Mairaj Ahmed Ansari; Nitika Paudel; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

10.  KSHV-induced notch components render endothelial and mural cell characteristics and cell survival.

Authors:  Ren Liu; Xiuqing Li; Anil Tulpule; Yue Zhou; Jeffrey S Scehnet; Shaobing Zhang; Jong-Soo Lee; Preet M Chaudhary; Jae Jung; Parkash S Gill
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.